ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SN. Smith & Nephew Plc

964.40
2.40 (0.25%)
Last Updated: 10:24:18
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.40 0.25% 964.40 964.40 964.60 965.60 948.40 954.80 194,122 10:24:18
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Ortho,prosth,surg Appl,suply 5.55B 263M 0.3011 31.89 8.39B
Smith & Nephew Plc is listed in the Ortho,prosth,surg Appl,suply sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 962p. Over the last year, Smith & Nephew shares have traded in a share price range of 887.00p to 1,316.00p.

Smith & Nephew currently has 873,398,889 shares in issue. The market capitalisation of Smith & Nephew is £8.39 billion. Smith & Nephew has a price to earnings ratio (PE ratio) of 31.89.

Smith & Nephew Share Discussion Threads

Showing 1301 to 1325 of 1325 messages
Chat Pages: 53  52  51  50  49  48  47  46  45  44  43  42  Older
DateSubjectAuthorDiscuss
16/4/2024
13:00
Anyone bothered to contact Investor Relations?
justiceforthemany
16/4/2024
11:33
Someone finally wants them
edwardt
15/4/2024
11:57
We could see a bounce at 9quid again. Good buying opp
knighty0001
12/4/2024
11:52
And he probably works from home too!
Suet

suetballs
12/4/2024
10:43
CEO asking for a 30% pay rise. What planet is this guy on!
knighty0001
11/4/2024
22:56
Stryker has grown its share price over 400% in that time. Perhaps we are in the wrong stock. At least we yield more but that's also the story of the uk market.
its the oxman
11/4/2024
22:40
c.10 years ago the price was much the same as it is today. Hard to believe.
its the oxman
11/4/2024
22:36
Have added a few, hard to see this so low, and surely chances have increased it will attract a bid,
its the oxman
09/4/2024
10:55
Disappointingly I'm sitting on a 30% loss.
I have bought more in the recent past but I just can't see a catalyst here.
The last results imo appeared to be more than ok to but since then .....
Bottom drawer for me - so I'm probably not the right person to proffer a view.
Suet

suetballs
08/4/2024
10:59
Anyone else tempted as these prices?
km1966
28/3/2024
16:47
Rather than expressing your unhappiness here stakeholders need to be proactive and speak to Investor Relations
Katherine (Head)
07811 270734

Deepak and his frequent share sales needs the boot for one.
Has Soames not bought any stock either?

justiceforthemany
28/3/2024
14:40
That's a major XD fall. Would like to invest but staying on the sidelines for now
dope007
28/3/2024
09:10
xd for 18p but down 36p.
Suet

suetballs
27/3/2024
17:19
Deepak.nath@smith-nephew.com
justiceforthemany
25/3/2024
16:59
Nope.
Who's contacted IR and the idiot CEO?

justiceforthemany
21/3/2024
17:29
Let's hope that cleared out the seller
edwardt
21/3/2024
16:39
This stock is completely out of favour.
CEO needs the boot.

justiceforthemany
06/3/2024
13:38
Interested to read this in Citywire
quote
he market has an ‘unconscious bias’ against Smith & Nephew (SN) and always assumes the worst about the medical technology company, says Liberum.

Analyst Seb Jantet retained his ‘buy’ recommendation and target price of £12.85 on the Citywire Elite Companies AA-rated provider of hip and knee implants, which rose 0.3% to £10.46 on Tuesday.

‘We are slightly perplexed by the market’s reaction to Smith & Nephew’s full-year results,’ Jantet said.

‘Trading was in line and there was a solid guide for full year 2024. And while the initial share price reaction was positive, the shares fell sharply over the next few days.

‘Understandable given Smith & Nephew’s track record, but it is this unconscious bias that is creating an interesting disconnect between the valuation and the fundamentals,’ said Jantet.

He added that ‘both the revenue and margin guides are achievable’ and said the ‘discount to peers is too high’.

cerrito
01/3/2024
16:42
So who's bothered to contact the CEO?
If you're a stakeholder you certainly should.

justiceforthemany
29/2/2024
17:46
CEO is on very thin ice here. Has been for a while. The discount to peers like Stryker is stark, assuming EPSA for 2024 comes in around 85c; 15x P/E.
Despite the Covid backlog shares remain super depressed and half their pre covid value.
CEO email below
Deepak.nath@smith-nephew.com

justiceforthemany
29/2/2024
12:41
Bought s small amount.
essentialinvestor
28/2/2024
23:21
Smith and nephew price about 13 dollars ,stryker 350 dollars so maybe no .
lonrho
28/2/2024
21:25
Stryker eps 8.25 dollarsS.N eps 0.828 centsSo maybe, yes.
pdriccio
28/2/2024
17:49
Stryker trades at 35x earnings.
This stock at 15x earnings.
Fair?

justiceforthemany
28/2/2024
09:15
Haha. Gone well that one. As has Hunting
dope007
Chat Pages: 53  52  51  50  49  48  47  46  45  44  43  42  Older

Your Recent History

Delayed Upgrade Clock